Thrivent Financial for Lutherans
VYNE icon

Thrivent Financial for Lutherans’s VYNE Therapeutics VYNE Stock Holding History

Thrivent Financial for Lutherans’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,059
Closed -$8K – 2511
2022
Q4 		$8K Hold
3,059
– – ﹤0.01% 2405
2022
Q3 		$12K Hold
3,059
– – ﹤0.01% 2399
2022
Q2 		$21K Sell
3,059
-591
-16% -$4.96K ﹤0.01% 2402
2022
Q1 		$42K Hold
3,650
– – ﹤0.01% 2488
2021
Q4 		$67K Sell
3,650
-349
-9% -$7.49K ﹤0.01% 2449
2021
Q3 		$101K Buy
3,999
+672
+20% +$26.1K ﹤0.01% 2452
2021
Q2 		$211K Buy
+3,327
New +$263K ﹤0.01% 2405

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Thrivent Financial for Lutherans's VYNE Position: Q1 2023 in Review

Thrivent Financial for Lutherans sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 3,059 shares — an estimated $8K sold.

Thrivent Financial for Lutherans first reported a position in VYNE in Q2 2021 and held it in 7 quarters. The position peaked at $211K in Q2 2021. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Thrivent Financial for Lutherans reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 3,059 VYNE Therapeutics shares in Q1 2023, an estimated $8K.
  • Thrivent Financial for Lutherans first reported a position in VYNE Therapeutics in Q2 2021 and held it in 7 quarters.
  • Thrivent Financial for Lutherans's VYNE Therapeutics position peaked at $211K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2023, filed 17 May 2023.